Biotest AG: Biotest AG opens eighth plasma collection center in the Czech Republic

DGAP-News: Biotest AG / Keyword (s): Miscellaneous

Biotest AG: Biotest AG opens eighth plasma collection center in the Czech Republic

12.01.2022 / 07:00
The sender is solely responsible for the content of this advertisement.


Biotest AG opens eighth plasma collection center in the Czech Republic

  • 28 plasma collection centers in Europe to ensure long-term plasma supply

Dreieich, January 12, 2022. Biotest has received the license to operate its eighth plasma collection center in the Czech Republic from the country’s national public health authority SUKL. The center is located in the commercial center of the important central Bohemian town of Kolín, near the historic main square and the Gothic dome.

In the state-of-the-art center with 15 donor beds, donors can watch TV or use Wi-Fi during the donation. The center is open 6 days a week, 12 hours a day.

Biotest continues to expand its own donation stations in order to increase its plasma collection capacity and create 15 new jobs in the Czech Republic. Plasma from the additional center will be used to support the future growth of the new production facility in Dreieich.

“We are very happy to be able to contribute to the ever increasing demand for human blood plasma with the opening of the state-of-the-art donation center in Kolín. Our current and future plasma donors, who continue to donate in our centers during the pandemic of Covid-19 and thus making an important contribution to the production of valuable plasma-based medicines deserve our very special thanks. I also especially thank them “, underlines Dr Frank Velte, Vice-President of Plasma Service Europe GmbH.

The collected plasma is processed exclusively at Biotest AG in Dreieich. Regular audits carried out in the Czech Republic ensure that high legal and internal quality requirements are met.

About human blood plasma
Human blood plasma is a raw material used to produce plasma-derived products, which are used to treat various diseases of the immune system, blood system, as well as in emergency medicine. Biotest ranks among the sixth largest manufacturing groups for plasma protein products in the world. Biotest is one of the world’s six largest manufacturers of plasma protein products.

About Biotest
Biotest is a supplier of plasma proteins and biological drugs. With an added value chain that spans from preclinical and clinical development to global sales, Biotest has specialized primarily in the areas of clinical immunology, hematology and critical care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preferred shares of Biotest AG are listed on the Prime Standard of the German Stock Exchange.

infrared contact
Dr Monika Buttkereit
Phone: + 49-6103-801-4406

PR contact
Dirk Neumüller
Phone: + 49-6103-801-269

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany,

Ordinary shares: securities identification number 522720; ISIN DE0005227201
Preference shares: security identification number 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Free market: Berlin, Düsseldorf, Hamburg / Hanover, Munich, Stuttgart, Tradegate

This document contains forward-looking statements on the overall economic development as well as on the activities, profits, financial situation and assets of Biotest AG and its subsidiaries. These statements are based on the company’s current plans, estimates, forecasts and expectations and are therefore subject to risks and uncertainties which could cause actual developments to deviate significantly from expected developments. Forward-looking statements speak only at the time of their publication. Biotest does not intend to update any forward-looking statements and assumes no obligation to do so.

01.12.2022 Distribution of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The sender is solely responsible for the content of this advertisement.

DGAP’s distribution services include regulatory announcements, financial / corporate news, and press releases.
Archives on

Comments are closed.